Your Messages Inbox
Your Article Summary
See Latest ArticlesA 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimers disease: a post hoc analysis
Current Medical Research and Opinion, 11/25/09
Farlow MR et al. – Use of the rivastigmine transdermal patch in patients on established memantine appears to be well–tolerated, with only modest, non–significant increases in AEs compared with monotherapy, and did not seem to affect cognition or global functioning adversely.
Related Articles
Does Diabetes Speed Up Memory Loss In Alzheimers Disease?
ScienceDaily, 10/28/09
Relevance Score: 71%
High Blood Pressure Likely in Alzheimers Offspring
MedLinePlus, 11/04/09
Relevance Score: 70%
Activated astrocytes: a therapeutic target in Alzheimer's disease?
Expert Review of Neurotherapeutics, 11/19/09
Relevance Score: 69%
Protective Role For Copper In Alzheimers Disease
ScienceDaily, 10/14/09
Relevance Score: 69%
All-trans retinoic acid as a novel therapeutic strategy for Alzheimer's disease
Expert Review of Neurotherapeutics, 11/19/09
Relevance Score: 68%
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Denosumab Demonstrated Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Prostate Cancer Patients With Bone Metastases
Amgen, 02/09/10
Choice of Starting Dose for Molecularly Targeted Agents Evaluated in First-in-Human Phase I Cancer Clinical Trials
Journal of Clinical Oncology, 02/05/10
BioMarin Reports Encouraging Preliminary Data on BMN 110 for MPS IVA
BioMarin, 02/05/10
Article Search
Sponsor